Last reviewed · How we verify
Dexmedetomidine Hydrochloride - Cycling
Dexmedetomidine Hydrochloride - Cycling is a Alpha-2 adrenergic agonist Small molecule drug developed by Vanderbilt University Medical Center. It is currently FDA-approved for Sedation of mechanically ventilated patients in intensive care units, Sedation and analgesia in perioperative settings. Also known as: Precedex.
Dexmedetomidine hydrochloride is a selective alpha-2 adrenergic agonist that produces sedation and analgesia by activating alpha-2 receptors in the central nervous system.
Dexmedetomidine hydrochloride is a selective alpha-2 adrenergic agonist that produces sedation and analgesia by activating alpha-2 receptors in the central nervous system. Used for Sedation of mechanically ventilated patients in intensive care units, Sedation and analgesia in perioperative settings.
At a glance
| Generic name | Dexmedetomidine Hydrochloride - Cycling |
|---|---|
| Also known as | Precedex |
| Sponsor | Vanderbilt University Medical Center |
| Drug class | Alpha-2 adrenergic agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Critical Care |
| Phase | FDA-approved |
Mechanism of action
Dexmedetomidine binds to alpha-2 adrenergic receptors in the locus coeruleus and other brain regions, reducing norepinephrine release and producing dose-dependent sedation, analgesia, and anxiolysis. The 'cycling' formulation refers to intermittent dosing protocols designed to maintain sedation while reducing tolerance and adverse effects associated with continuous infusion. It is commonly used in intensive care settings for sedation of mechanically ventilated patients.
Approved indications
- Sedation of mechanically ventilated patients in intensive care units
- Sedation and analgesia in perioperative settings
Common side effects
- Hypotension
- Bradycardia
- Hypertension (initial)
- Dry mouth
- Rebound hypertension on discontinuation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine Hydrochloride - Cycling CI brief — competitive landscape report
- Dexmedetomidine Hydrochloride - Cycling updates RSS · CI watch RSS
- Vanderbilt University Medical Center portfolio CI
Frequently asked questions about Dexmedetomidine Hydrochloride - Cycling
What is Dexmedetomidine Hydrochloride - Cycling?
How does Dexmedetomidine Hydrochloride - Cycling work?
What is Dexmedetomidine Hydrochloride - Cycling used for?
Who makes Dexmedetomidine Hydrochloride - Cycling?
Is Dexmedetomidine Hydrochloride - Cycling also known as anything else?
What drug class is Dexmedetomidine Hydrochloride - Cycling in?
What development phase is Dexmedetomidine Hydrochloride - Cycling in?
What are the side effects of Dexmedetomidine Hydrochloride - Cycling?
What does Dexmedetomidine Hydrochloride - Cycling target?
Related
- Drug class: All Alpha-2 adrenergic agonist drugs
- Target: All drugs targeting Alpha-2 adrenergic receptor
- Manufacturer: Vanderbilt University Medical Center — full pipeline
- Therapeutic area: All drugs in Anesthesia/Critical Care
- Indication: Drugs for Sedation of mechanically ventilated patients in intensive care units
- Indication: Drugs for Sedation and analgesia in perioperative settings
- Also known as: Precedex
- Compare: Dexmedetomidine Hydrochloride - Cycling vs similar drugs
- Pricing: Dexmedetomidine Hydrochloride - Cycling cost, discount & access